Jin Q. Cheng, MD, PhD

A major interest of our laboratory is to study the genetic alterations and their molecular mechanisms in human ovarian and breast cancer. Specifically, we are interested in elucidation of normal cellular function of the PI3K/Akt and Aurora-A pathways and to characterize their role in human ovarian carcinogenesis. In particular, we are focusing on the identification of molecules that are specifically regulated by Akt or Aurora-A as well as the molecules that are regulated by PI3K/PTEN but not Akt. We are also interested in the identification of small molecule inhibitors of Akt and Aurora-A for cancer intervention. In addition, we are also working on the role of microRNA and a newly identified NGB tumor suppressor gene in human cancer.

• Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY, Cheng JQ. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2013 Jan. Pubmedid: 23353819.
• Guo J, Kim D, Gao J, Kurtyka C, Chen H, Yu C, Wu D, Mittal A, Beg AA, Chellappan SP, Haura EB, Cheng JQ. IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. Oncogene. 2013 Jan;32(2):151-159. Pubmedid: 22330135.
• Xu CX, Xu M, Tan L, Yang H, Permuth-Wey J, Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA, Cheng JQ. MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J Biol Chem. 2012 Dec;287(42):34970-34978. Pubmedid: 22927443. Pmcid: PMC3471722.
• Cui G, Park S, Badeaux AI, Kim D, Lee J, Thompson JR, Yan F, Kaneko S, Yuan Z, Botuyan MV, Bedford MT, Cheng JQ, Mer G. PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53. Nat Struct Mol Biol. 2012 Nov;19(9):916-924. Pubmedid: 22864287. Pmcid: PMC3454513.
• Koren J, Miyata Y, Kiray J, O'Leary JC, Nguyen L, Guo J, Blair LJ, Li X, Jinwal UK, Cheng JQ, Gestwicki JE, Dickey CA. Rhodacyanine derivative selectively targets cancer cells and overcomes tamoxifen resistance. PLoS One. 2012 Sep;7(4):e35566. Pubmedid: 22563386. Pmcid: PMC3338522.
• Lawrence HR, Martin MP, Luo Y, Pireddu R, Yang H, Gevariya H, Ozcan S, Zhu JY, Kendig R, Rodriguez M, Elias R, Cheng JQ, Sebti SM, Schonbrunn E, Lawrence NJ. Development of o-Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors. J Med Chem. 2012 Sep;55(17):7392-7416. Pubmedid: 22803810.
• Park S, Kim D, Dan HC, Chen H, Testa JR, Cheng JQ. Identification of Akt interaction protein PHF20/TZP that transcriptionally regulates p53. J Biol Chem. 2012 Sep;287(14):11151-11163. Pubmedid: 22334668. Pmcid: PMC3322870.
• Jung HM, Phillips BL, Patel RS, Cohen DM, Jakymiw A, Kong WW, Cheng JQ, Chan EK. Keratinization-associated miR-7 and miR-21 regulate tumor suppressor reversion-inducing cysteine-rich protein with kazal motifs (RECK) in oral cancer. J Biol Chem. 2012 Aug;287(35):29261-29272. Pubmedid: 22761427. Pmcid: PMC3436145.
• Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, Koomen JM. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma. Mol Cell Proteomics. 2012 Mar;10(11):M110.005520. Pubmedid: 21846842. Pmcid: PMC3226396.
• Permuth-Wey J, Chen Z, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Chanock SJ, Cramer DW, Cunningham JM, Fenstermacher D, Fridley BL, Garcia-Closas M, Gayther SA, Gentry-Maharaj A, Gonzalez-Bosquet J, Iversen E, Jim H, McLaughlin J, Menon U, Narod SA, Phelan CM, Ramus SJ, Risch H, Song H, Sutphen R, Terry KL, Tyrer J, Vierkant RA, Wentzensen N, Lancaster JM, Cheng JQ, Berchuck A, Pharoah PD, Schildkraut JM, Goode EL, Sellers TA. MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2012 Feb;20(8):1793-1797. Pubmedid: 21636674. Pmcid: PMC3153581.
• Koren J, Miyata Y, Kiray J, O'Leary JC, Nguyen L, Guo J, Blair LJ, Li X, Jinwal UK, Cheng JQ, Gestwicki JE, Dickey CA. Correction: Rhodacyanine Derivative Selectively Targets Cancer Cells and Overcomes Tamoxifen Resistance. PLoS One. 2012;7(7). Pubmedid: 22815661.
• Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs. 2011 Dec;29(6):1381-1389. Pubmedid: 20644979.
• Patel RS, Jakymiw A, Yao B, Pauley BA, Carcamo WC, Katz J, Cheng JQ, Chan EK. High resolution of microRNA signatures in human whole saliva. Arch Oral Biol. 2011 Dec;56(12):1506-1513. Pubmedid: 21704302. Pmcid: PMC3189266.
• Guo JP, Coppola D, Cheng JQ. IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem. 2011 Oct;286(43):37389-37398. Pubmedid: 21908616. Pmcid: PMC3199486.
• Permuth-Wey J, Kim D, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Bloom G, Chanock SJ, Chen Z, Cramer DW, Cunningham JM, Dagne G, Ebbert-Syfrett J, Fenstermacher D, Fridley BL, Garcia-Closas M, Gayther SA, Ge W, Gentry-Maharaj A, Gonzalez-Bosquet J, Goode EL, Iversen E, Jim H, Kong W, McLaughlin J, Menon U, Monteiro AN, Narod SA, Pharoah PD, Phelan CM, Qu X, Ramus SJ, Risch H, Schildkraut JM, Song H, Stockwell H, Sutphen R, Terry KL, Tyrer J, Vierkant RA, Wentzensen N, Lancaster JM, Cheng JQ, Sellers TA. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res. 2011 Sep;71(11):3896-3903. Pubmedid: 21482675. Pmcid: PMC3107389.
• Cross B, Chen L, Cheng Q, Li B, Yuan ZM, Chen J. Inhibition of p53 DNA binding function by the MDM2 protein acidic domain. J Biol Chem. 2011 Jul;286(18):16018-16029. Pubmedid: 21454483. Pmcid: PMC3091211.
• Balasis ME, Forinash KD, Chen YA, Fulp WJ, Coppola D, Hamilton AD, Cheng JQ, Sebti SM. Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clin Cancer Res. 2011 May;17(9):2852-2862. Pubmedid: 21536547. Pmcid: PMC3156694.
• Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C, Muraoka-Cook RS, Cheng JQ, Schönbrunn E, Sebti SM, Earp HS, Mahajan NP. Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One. 2011 Jan;5(3):e9646. Pubmedid: 20333297. Pmcid: PMC2841635.
• Berndt N, Yang H, Trinczek B, Betzi S, Zhang Z, Wu B, Lawrence NJ, Pellecchia M, Schönbrunn E, Cheng JQ, Sebti SM. The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ. 2010 Nov;17(11):1795-1804. Pubmedid: 20489726. Pmcid: PMC2952662.
• Shu SK, Liu Q, Coppola D, Cheng JQ. Phosphorylation and activation of androgen receptor by Aurora-A. J Biol Chem. 2010 Nov;285(43):33045-33053. Pubmedid: 20713353. Pmcid: PMC2963369.
• Zhong B, Sallman DA, Gilvary DL, Pernazza D, Sahakian E, Fritz D, Cheng JQ, Trougakos I, Wei S, Djeu JY. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells. Mol Cancer Ther. 2010 Sep;9(6):1831-1841. Pubmedid: 20501799.
• Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, Cheng JQ. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem. 2010 Jun;285(23):17869-17879. Pubmedid: 20371610. Pmcid: PMC2878550.
• Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, Sotomayor E, Tao J, Cheng JQ. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010 Apr;115(13):2630-2639. Pubmedid: 20086245. Pmcid: PMC2852365.
• Kim D, Sun M, He L, Zhou QH, Chen J, Sun XM, Bepler G, Sebti SM, Cheng JQ. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. J Biol Chem. 2010 Apr;285(11):8383-8394. Pubmedid: 20068047. Pmcid: PMC2832988.
• Kim D, Shu S, Coppola MD, Kaneko S, Yuan ZQ, Cheng JQ. Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1-Akt pathway. PLoS One. 2010 Mar;5(3):e9616. Pubmedid: 20231902. Pmcid: PMC2834758.
• Guo JP, Shu SK, Esposito NN, Coppola D, Koomen JM, Cheng JQ. IKKepsilon phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer. J Biol Chem. 2010 Feb;285(6):3676-3684. Pubmedid: 19940156. Pmcid: PMC2823508.
• Yuan Z, Kim D, Shu S, Wu J, Guo J, Xiao L, Kaneko S, Coppola D, Cheng JQ. Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic signaling through phosphorylation of threonine 120. J Biol Chem. 2010 Feb;285(6):3815-3824. Pubmedid: 19940129. Pmcid: PMC2823523.
• Koren J, Jinwal UK, Jin Y, O'Leary J, Jones JR, Johnson AG, Blair LJ, Abisambra JF, Chang L, Miyata Y, Cheng AM, Guo J, Cheng JQ, Gestwicki JE, Dickey CA. Facilitating Akt clearance via manipulation of Hsp70 activity and levels. J Biol Chem. 2010 Jan;285(4):2498-2505. Pubmedid: 19889640. Pmcid: PMC2807306.
• Guo JP, Shu SK, He L, Lee YC, Kruk PA, Grenman S, Nicosia SV, Mor G, Schell MJ, Coppola D, Cheng JQ. Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol. 2009 Jul;175(1):324-333. Pubmedid: 19497997. Pmcid: PMC2708818.
• Mohapatra S, Chu B, Zhao X, Djeu J, Cheng JQ, Pledger WJ. Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitors. Int J Biochem Cell Biol. 2009 Mar;41(3):595-602. Pubmedid: 18708158.
• Kayser-Bricker KJ, Glenn MP, Lee SH, Sebti SM, Cheng JQ, Hamilton AD. Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents. Bioorg Med Chem. 2009 Feb;17(4):1764-1771. Pubmedid: 19179081.
• Park S, Guo J, Kim D, Cheng JQ. Identification of 24p3 as a direct target of Foxo3a regulated by interleukin-3 through the phosphoinositide 3-kinase/Akt pathway. J Biol Chem. 2009 Jan;284(4):2187-2193. Pubmedid: 19056725. Pmcid: PMC2629101.
• Zhang Y, Zhang M, Dong H, Yong S, Li X, Olashaw N, Kruk PA, Cheng JQ, Bai W, Chen J, Nicosia SV, Zhang X. Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene. 2009 Jan;28(3):445-460. Pubmedid: 18850005.
• Kong W, Zhao JJ, He L, Cheng JQ. Strategies for profiling microRNA expression. J Cell Physiol. 2009 Jan;218(1):22-25. Pubmedid: 18767038.
• Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008 Dec;283(45):31079-31086. Pubmedid: 18790736. Pmcid: PMC2576549.
• Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ. MicroRNA-155 Is regulated by transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008 Nov;28(22):6773-6784. Pubmedid: 18794355.
• He L, Yang H, Ma Y, Pledger WJ, Cress WD, Cheng JQ. Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression. J Biol Chem. 2008 Nov;283(45):31012-31020. Pubmedid: 18776222. Pmcid: PMC2576560.
• Garden AS, Harris J, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS, Ang KK. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys. 2008 Aug;71(5):1351-1355. Pubmedid: 18640496. Pmcid: PMC2582390.
• Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, Mansour M, Xu LM, Costanzo C, Cheng JQ, Wang LH. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem. 2008 May;283(21):14665-14673. Pubmedid: 18353781.
• Dickey CA, Koren J, Zhang YJ, Xu YF, Jinwal UK, Birnbaum MJ, Monks B, Sun M, Cheng JQ, Patterson C, Bailey RM, Dunmore J, Soresh S, Leon C, Morgan D, Petrucelli L. Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A. 2008 Mar;105(9):3622-3627. Pubmedid: 18292230. Pmcid: PMC2265134.
• Cheng GZ, Park S, Shu S, He L, Kong W, Zhang W, Yuan Z, Wang LH, Cheng JQ. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets. 2008 Feb;8(1):2-6. Pubmedid: 18288938.
• Cheng J. Akt pathway in oncogenesis and anti-cancer therapy. Curr Cancer Drug Targets. 2008 Feb;8(1):1-1. Pubmedid: 18288937.
• Bermudez Y, Yang H, Cheng JQ, Kruk PA. Pyk2/ERK 1/2 mediate Sp1- and c-Myc-dependent induction of telomerase activity by epidermal growth factor. Growth Factors. 2008 Feb;26(1):1-11. Pubmedid: 18365874.
• Ren Y, Chen Z, Chen L, Woods NT, Reuther GW, Cheng JQ, Wang HG, Wu J. Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL. J Biol Chem. 2008 Feb;282(50):36463-36473. Pubmedid: 17942397. Pmcid: PMC3000740.
• Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008 Jan;68(2):425-433. Pubmedid: 18199536.
• Park J, Zheng W, Kim D, Cheng J, Kumar N, Ahmad N, Pow-Sang J. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev. 2007 Nov;31(5):359-365. Pubmedid: 18037591.
• Naidu K, Fang Q, Naidu K, Cheng J, Nicosia S, Coppola D. P53 enhances ascorbyl stearate-induced G2/M arrest of human ovarian cancer cells. Anticancer Res. 2007 Nov;27(6B):3927-3934. Pubmedid: 18225552.
• Takahashi Y, Coppola D, Matsushita N, Cualing HD, Sun M, Sato Y, Liang C, Jung JU, Cheng JQ, Mule JJ, Pledger WJ, Wang HG. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol. 2007 Oct;9(10):1142-1151. Pubmedid: 17891140. Pmcid: PMC2254521.
• Sagatys E, Garrett CR, Boulware D, Kelley S, Malafa M, Cheng JQ, Sebti S, Coppola D. Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia. Hum Pathol. 2007 Oct;38(10):1526-1531. Pubmedid: 17640711.
• Saglam O, Garrett CR, Boulware D, Sayegh Z, Shibata D, Malafa M, Yeatman T, Cheng JQ, Sebti S, Coppola D. Activation of the serine/threonine protein kinase AKT during the progression of colorectal neoplasia. Clin Colorectal Cancer. 2007 Sep;6(9):652-656. Pubmedid: 17945038.
• Bermudez Y, Yang H, Saunders BO, Cheng JQ, Nicosia SV, Kruk PA. VEGF- and LPA-induced telomerase in human ovarian cancer cells is Sp1-dependent. Gynecol Oncol. 2007 Sep;106(3):526-537. Pubmedid: 17559911.
• Ghosh N, Patel N, Jiang K, Watson JE, Cheng J, Chalfant CE, Cooper DR. Ceramide-activated protein phosphatase involvement in insulin resistance via Akt, serine/arginine-rich protein 40, and ribonucleic acid splicing in L6 skeletal muscle cells. Endocrinology. 2007 Apr;148(3):1359-1366. Pubmedid: 17158207. Pmcid: PMC2664306.
• Kayser KJ, Glenn MP, Sebti SM, Cheng JQ, Hamilton AD. Modifications of the GSK3beta substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics. Bioorg Med Chem Lett. 2007 Apr;17(7):2068-2073. Pubmedid: 17276059.
• Yang L, Sun M, Sun XM, Cheng GZ, Nicosia SV, Cheng JQ. Akt attenuation of the serine protease activity of HtrA2/Omi through phosphorylation of serine-212. J Biol Chem. 2007 Apr;282(15):10981-10987. Pubmedid: 17311912.
• Lee H, Kim D, Dan HC, Wu EL, Gritsko TM, Cao C, Nicosia SV, Golemis EA, Liu W, Coppola D, Brem SS, Testa JR, Cheng JQ. Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein. Mol Cell Biol. 2007 Mar;27(6):2103-2119. Pubmedid: 17210637. Pmcid: PMC1820506.
• Yang H, He L, Kruk P, Nicosia SV, Cheng JQ. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer. 2006 Nov;119(10):2304-2312. Pubmedid: 16894566.
• Karst AM, Dai DL, Cheng JQ, Li G. Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis, and patient survival. Cancer Res. 2006 Sep;66(18):9221-9226. Pubmedid: 16982766.
• Wang G, Barrett JW, Stanford M, Werden SJ, Johnston JB, Gao X, Sun M, Cheng JW, McFadden G. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A. 2006 May;103(12):4640-4645. Pubmedid: 16537421. Pmcid: PMC1450224.
• Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S, Muro-Cacho CA, Jove R. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006 Jan;12(1):11-19. Pubmedid: 16397018.
• Pu P, Kang C, Li J, Jiang H, Cheng J. The Effects of Antisense AKT2 RNA on the Inhibition of Malignant Glioma Cell Growth in vitro and in vivo. J Neurooncol. 2006 Jan;76(1):1-11. Pubmedid: 16402276.
• Fang Q, Naidu KA, Naidu KA, Zhao H, Sun M, Dan HC, Nasir A, Kaiser HE, Cheng JQ, Nicosia SV, Coppola D. Ascorbyl stearate inhibits cell proliferation and tumor growth in human ovarian carcinoma cells by targeting the PI3K/AKT pathway. Anticancer Res. 2006 Jan;26(1A):203-209. Pubmedid: 16475700.
• Kim D, Cheng GZ, Lindsley CW, Yang H, Cheng JQ. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr Opin Investig Drugs. 2005 Dec;6(12):1250-1258. Pubmedid: 16370391.
• Park S, Kim D, Kaneko S, Szewczyk KM, Nicosia SV, Yu H, Jove R, Cheng JQ. Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway. J Biol Chem. 2005 Nov;280(47):38932-38941. Pubmedid: 16174774.
• Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene. 2005 Nov;24(50):7482-7492. Pubmedid: 16288295.
• Niesen MI, Osborne AR, Yang H, Rastogi S, Chellappan S, Cheng JQ, Boss JM, Blanck G. Activation of a methylated promoter mediated by a sequence-specific DNA-binding protein, RFX. J Biol Chem. 2005 Nov;280(47):38914-38922. Pubmedid: 16166088.
• Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005 Oct;65(20):9185-9189. Pubmedid: 16230377.
• Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, Cheng JQ, Jove R, Yu H. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005 Aug;24(36):5552-5560. Pubmedid: 16007214.
• Nam S, Buettner R, Turkson J, Kim D, Cheng JQ, Muehlbeyer S, Hippe F, Vatter S, Merz KH, Eisenbrand G, Jove R. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A. 2005 Jul;102(17):5998-6003. Pubmedid: 15837920. Pmcid: PMC1087919.
• Yang H, Zheng S, Meijer L, Li SM, Leclerc S, Yu LL, Cheng JQ, Zhang S. Screening the active constituents of Chinese medicinal herbs as potent inhibitors of Cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2 kinase. J Zhejiang Univ Sci B. 2005 Jul;6(7):656-663. Pubmedid: 15973768. Pmcid: PMC1389800.
• Yuan ZQ, Kim D, Kaneko S, Sussman M, Bokoch GM, Kruh GD, Nicosia SV, Testa JR, Cheng JQ. ArgBP2gamma interacts with Akt and p21-activated kinase-1 and promotes cell survival. J Biol Chem. 2005 Jun;280(22):21483-21490. Pubmedid: 15784622.
• Ang K, Harris J, Garden A, Trotti A, Jones C, Carrascosa L, Cheng J, Spencer S, Forastiere A, Weber R. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol. 2005 May;23(13):3008-3015. Pubmedid: 15860857.
• Patel NA, Kaneko S, Apostolatos HS, Bae SS, Watson JE, Davidowitz K, Chappell DS, Birnbaum MJ, Cheng JQ, Cooper DR. Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CbetaII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40. J Biol Chem. 2005 Apr;280(14):14302-14309. Pubmedid: 15684423.
• Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, Nicosia SV, Cheng JQ. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci. 2005 Jan;10:975-987. Pubmedid: 15569636.
• Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, Cheng JQ. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem. 2004 Dec;279(50):52175-52182. Pubmedid: 15469940.
• Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, KesterM, Sandirasegarane L, Robertson GP. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004 Oct;64(19):7002-7010. Pubmedid: 15466193.
• Johnson NC, Dan HC, Cheng JQ, Kruk PA. BRCA1 185delAG mutation inhibits Akt-dependent, IAP-mediated caspase 3 inactivation in human ovarian surface epithelial cells. Exp Cell Res. 2004 Aug;298(1):9-16. Pubmedid: 15242757.
• Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, Sebti SM, Cheng JQ. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 2004 Jul;64(13):4394-4399. Pubmedid: 15231645.
• Jiang K, Sun J, Cheng J, Djeu JY, Wei S, Sebti S. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol Cell Biol. 2004 Jun;24(12):5565-5576. Pubmedid: 15169915. Pmcid: PMC419878.
• Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, Tsang BK, Cheng JQ. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem. 2004 Feb;279(7):5405-5412. Pubmedid: 14645242.
• Yang H, Ou CC, Feldman RI, Nicosia SV, Kruk PA, Cheng JQ. Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res. 2004 Jan;64(2):463-467. Pubmedid: 14744757.
• Dan HC, Jiang K, Coppola D, Hamilton A, Nicosia SV, Sebti SM, Cheng JQ. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene. 2004 Jan;23(3):706-715. Pubmedid: 14737105.
• Nicosia S, Wilbanks G, Saunders B, Mayer J, Cardosi R, Kruk P, Cheng J, Bai W, Coppola D, Fiorica J. Cytology of human ovarian surface epithelial brushings. Cancer Cytopathol. 2004;102(1):1-10. Pubmedid: 14968412.
• Sekharam M, Zhao H, Sun M, Fang Q, Zhang Q, Yuan Z, Dan HC, Boulware D, Cheng JQ, Coppola D. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res. 2003 Nov;63(22):7708-7716. Pubmedid: 14633695.
• Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res. 2003 Nov;63(21):7081-7088. Pubmedid: 14612499.
• Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem. 2003 Oct;278(44):42992-43000. Pubmedid: 12933816.
• Iravani S, Zhang HQ, Yuan ZQ, Cheng JQ, Karl RC, Jove R, Coppola D. Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia. Hum Pathol. 2003 Oct;34(10):975-982. Pubmedid: 14608530.
• Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem. 2003 Jun;278(26):23432-23440. Pubmedid: 12697749.
• Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, Fiorica JV, Nicosia SV, Cheng JQ. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res. 2003 Apr;9(4):1420-1426. Pubmedid: 12684414.
• Nicosia S, Bai W, Cheng J, Coppola D, Kruk P. Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am. 2003;17(4):927-943. Pubmedid: 12959183.
• Chen T, Yang I, Irby R, Shain K, Wang H, Quackenbush J, Coppola D, Cheng JQ, Yeatman T. Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Res. 2003;63(15):4368-4374. Pubmedid: 12907606.
• Dan HC, Sun M, Yang L, Feldman RI, Sui XM, Ou CC, Nellist M, Yeung RS, Halley DJ, Nicosia SV, Pledger WJ, Cheng JQ. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem. 2002 Sep;277(38):35364-35370. Pubmedid: 12167664.
• Alfonso-De Matte MY, Yang H, Evans MS, Cheng JQ, Kruk PA. Telomerase is regulated by c-Jun NH2-terminal kinase in ovarian surface epithelial cells. Cancer Res. 2002 Aug;62(16):4575-4578. Pubmedid: 12183409.
• Yuan ZQ, Feldman RI, Sun M, Olashaw NE, Coppola D, Sussman GE, Shelley SA, Nicosia SV, Cheng JQ. Inhibition of JNK by cellular stress- and tumor necrosis factor alpha-induced AKT2 through activation of the NF kappa B pathway in human epithelial Cells. J Biol Chem. 2002 Aug;277(33):29973-29982. Pubmedid: 12048203.
• Cheng JQ, Jiang X, Fraser M, Li M, Dan HC, Sun M, Tsang BK. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist Updat. 2002 Jul;5(3-4):131-146. Pubmedid: 12237081.
• Kaneko S, Feldman RI, Yu L, Wu Z, Gritsko T, Shelley SA, Nicosia SV, Nobori T, Cheng JQ. Positive feedback regulation between Akt2 and MyoD during muscle differentiation. Cloning of Akt2 promoter. J Biol Chem. 2002 Jun;277(26):23230-23235. Pubmedid: 11948187.
• Zhong Y, Cheng J, Wang G, Tian X, Chen X, Liu Y, Li L, Zhang L, Chen J. [Epitope mapping of hepatitis C virus non-structure protein 5 from a 7 peptidephage library by using immobilized specific monoclonal antibody]Zhonghua Gan Zang Bing Za Zhi. 2002;10:266-8. Ch. Pubmedid: 12223135.
• Fox P, Cheng J, Lu J. Fourier-Bessel field calculation and tuning of a CW annular array. Ieee Trans Ultrason Ferroelectr Freq Control. 2002;49:1179-1190. Pubmedid: 12243569.
• Li K, Wang L, Cheng J, Lu Y, Zhang L, Mou J, Hong Y, Liu Y, Duan H, WangG, Li L, Chen J. [Mutual interaction between hepatitis C virus core protein and translin, arecombination hotspot binding protein]Zhonghua Yi Xue Za Zhi. 2002;82:673-7. Ch. Pubmedid: 12133464.
• Li K, Wang L, Cheng J, Lu Y, Zhang L, Mou J, Hong Y, Liu Y, Duan H, Wang G, Li L, Chen J. [Mutual interaction between hepatitis C virus core protein and translin, arecombination hotspot binding protein] Chinese. Zhonghua Yi Xua Za Zhi. 2002;82:673-677. Pubmedid: 12133464.
• Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res. 2001 Aug;61(16):5985-5991. Pubmedid: 11507039.
• Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol. 2001 Aug;159(2):431-437. Pubmedid: 11485901. Pmcid: PMC1850562.
• Alfonso-De Matte M, Cheng J, Kruk P. Ultraviolet irradiation- and dimethyl sulfoxide-induced telomerase activity in ovarian epithelial cell lines. Exp Cell Res. 2001;267(1):13-27. Pubmedid: 11412034.
• Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV, Cheng JQ. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene. 2000 May;19(19):2324-2330. Pubmedid: 10822383.
• Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM, Cheng JQ. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol. 2000 Jan;20(1):139-148. Pubmedid: 10594016. Pmcid: PMC85069.
• Kubo A, Nakagawa K, Varma RK, Conrad NK, Cheng JQ, Lee WC, Testa JR, Johnson BE, Kaye FJ, Kelley MJ. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 1999 Dec;5(12):4279-4286. Pubmedid: 10632371.
• Cheng J, Lee W, Klein M, Cheng G, Jhanwar S, Testa J. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosom Cancer. 1999;24(3):238-242. Pubmedid: 10451704.
• Liu AX, Testa JR, Hamilton TC, Jove R, Nicosia SV, Cheng JQ. AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res. 1998 Jul;58(14):2973-2977. Pubmedid: 9679957.
• Altomare DA, Lyons GE, Mitsuuchi Y, Cheng JQ, Testa JR. Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin. Oncogene. 1998 May;16(18):2407-2411. Pubmedid: 9620559.
• Cheng JQ, Jiang W, Hackney DD. Interaction of mant-adenosine nucleotides and magnesium with kinesin. Biochemistry. 1998 Apr;37(15):5288-5295. Pubmedid: 9548760.
• Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog. 1998 Feb;21(2):81-86. Pubmedid: 9496907.
• Ruggeri B, Huang L, Wood M, Cheng J, Testa J. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog. 1998;211(2):81-86. Pubmedid: noPMID.
• Cheng JQ, Altomare DA, Klein MA, Lee WC, Kruh GD, Lissy NA, Testa JR. Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene. 1997 Jun;14(23):2793-2801. Pubmedid: 9190895.
• Testa J, Liu Z, Feder M, Bell D, Balsara B, Cheng J, Taguchi T. Advances in the analysis of chromosome alterations in human lung carcinomas. Cancer Genet Cytogenet. 1997;95:20-32. Pubmedid: 9140450.
• Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A. 1996 Apr;93(8):3636-3641. Pubmedid: 8622988. Pmcid: PMC39663.
• Altomare DA, Guo K, Cheng JQ, Sonoda G, Walsh K, Testa JR. Cloning, chromosomal localization and expression analysis of the mouse Akt2 oncogene. Oncogene. 1995 Sep;11(6):1055-1060. Pubmedid: 7566964.
• Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A. 1992 Oct;89(19):9267-9271. Pubmedid: 1409633. Pmcid: PMC50107.
• Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Ann Chen Y, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Górski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Høgdall CK, Høgdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeney LA, Kikkawa F, Konecny GE, Krakstad C, Krüger Kjaer S, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Kiong Lim B, Lin J, Lissowska J, Lu KH, Lubiński J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlow I, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Anne Rossing ...
• Wang J, Cheng J. A simple method for profiling miRNA expression. Methods Mol Biol. 2008 414;414:183-190. Pubmedid: 18175820.